756 related articles for article (PubMed ID: 27866217)
1. Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
Sánchez A; Blanco R
Osteoporos Int; 2017 Mar; 28(3):1145-1147. PubMed ID: 27866217
[TBL] [Abstract][Full Text] [Related]
2. Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis.
Chiu WY; Lee JJ; Tsai KS
J Clin Endocrinol Metab; 2013 Apr; 98(4):E723-6. PubMed ID: 23471975
[TBL] [Abstract][Full Text] [Related]
3. Femoral fracture and temporomandibular joint destruction following the use of bisphosphonates.
Skoglund K; Hjortdal O
Tidsskr Nor Laegeforen; 2015 Jan; 135(2):116-7. PubMed ID: 25625987
[No Abstract] [Full Text] [Related]
4. Strontium ranelate treatment in a postmenopausal woman with osteonecrosis of the jaw after long-term oral bisphosphonate administration: a case report.
Pan WL; Chen PL; Lin CY; Pan YC; Ju YR; Chan CP; Hsu RW
Clin Interv Aging; 2017; 12():1089-1093. PubMed ID: 28744112
[TBL] [Abstract][Full Text] [Related]
5. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
Grbic JT; Landesberg R; Lin SQ; Mesenbrink P; Reid IR; Leung PC; Casas N; Recknor CP; Hua Y; Delmas PD; Eriksen EF;
J Am Dent Assoc; 2008 Jan; 139(1):32-40. PubMed ID: 18167382
[TBL] [Abstract][Full Text] [Related]
6. [Subtrochanteric pathological fracture on bisphosphonates].
Mathonet PY; Willems S; Ciornohac JF
Rev Med Liege; 2018 Feb; 73(2):56-60. PubMed ID: 29517866
[TBL] [Abstract][Full Text] [Related]
7. Going on a drug holiday?
Bonnick SL
J Clin Densitom; 2011; 14(4):377-83. PubMed ID: 22051091
[No Abstract] [Full Text] [Related]
8. Concurrent bisphosphonate-related bilateral atypical subtrochanteric fractures and osteonecrosis of the jaw on bone scintigraphy.
Kim JE; Yun M; Lim SK; Rhee Y
Clin Nucl Med; 2015 May; 40(5):450-2. PubMed ID: 25706787
[TBL] [Abstract][Full Text] [Related]
9. A Case Report of Oral Bisphosphonate Treatment for Osteoporosis Leading to Atypical Femoral Fracture and Pathologic Mandibular Fracture.
Fernandes TL; Viezzer Fernandes B; Jitumori C; Franco GCN
Am J Case Rep; 2023 Oct; 24():e941144. PubMed ID: 37867315
[TBL] [Abstract][Full Text] [Related]
10. [Treatment with bisphosphonates as a possible cause of bilateral spontaneous atypical femoral fracture].
Rasmussen M; Lange J
Ugeskr Laeger; 2012 Jan; 174(1-2):32-3. PubMed ID: 22233718
[TBL] [Abstract][Full Text] [Related]
11. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
12. Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases.
Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E
Quintessence Int; 2016; 47(5):433-40. PubMed ID: 26665262
[TBL] [Abstract][Full Text] [Related]
13. Salvage of failed osteosynthesis for an atypical subtrochanteric femoral fracture associated with long-term bisphosphonate treatment using a 95° angled blade plate.
Kim SM; Rhyu KH; Lim SJ
Bone Joint J; 2018 Nov; 100-B(11):1511-1517. PubMed ID: 30418051
[TBL] [Abstract][Full Text] [Related]
14. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.
Grbic JT; Black DM; Lyles KW; Reid DM; Orwoll E; McClung M; Bucci-Rechtweg C; Su G
J Am Dent Assoc; 2010 Nov; 141(11):1365-70. PubMed ID: 21037195
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Fitzpatrick SG; Stavropoulos MF; Bowers LM; Neuman AN; Hinkson DW; Green JG; Bhattacharyya I; Cohen DM
J Oral Maxillofac Surg; 2012 Feb; 70(2):325-30. PubMed ID: 21723015
[No Abstract] [Full Text] [Related]
16. Bisphosphonate-associated atypical subtrochanteric femur fractures in the older patient.
Gopal GK; Tam KL; Krishnan SP; Maddern IL
N Z Med J; 2014 Feb; 127(1389):81-5. PubMed ID: 24548959
[TBL] [Abstract][Full Text] [Related]
17. Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients.
Voss PJ; Joshi Oshero J; Kovalova-Müller A; Veigel Merino EA; Sauerbier S; Al-Jamali J; Lemound J; Metzger MC; Schmelzeisen R
J Craniomaxillofac Surg; 2012 Dec; 40(8):719-25. PubMed ID: 22336489
[TBL] [Abstract][Full Text] [Related]
18. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
[TBL] [Abstract][Full Text] [Related]
19. Effect of local vs. systemic bisphosphonate delivery on dental implant fixation in a model of osteonecrosis of the jaw.
Abtahi J; Agholme F; Sandberg O; Aspenberg P
J Dent Res; 2013 Mar; 92(3):279-83. PubMed ID: 23264610
[TBL] [Abstract][Full Text] [Related]
20. Complications of new medications.
Roldan CJ; Paniagua L
West J Emerg Med; 2015 Jan; 16(1):154-6. PubMed ID: 25671027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
